Deutsch-Wenzel R P, Brune H, Grimmer G
Cancer Lett. 1983 Aug;20(1):97-101. doi: 10.1016/0304-3835(83)90193-3.
Using a beeswax/tricaprylin mixture as vehicle, three doses each of acridine, benz[a]acridine (BaAC), benz[c]acridine (BcAC), dibenz[a,h]-acridine (DBa,hAC) and dibenz[a,j]acridine (DBa,jAC) were injected into the lungs of 35 female Osborne-Mendel rats per group. To compare the carcinogenic potency of the heterocycles, benzo[a]pyrene (BaP) was taken as reference substance. Dose-response relationships were obtained for DBa,hAC as well as for BaP. DBa,jAC and BcAC exhibited no carcinogenic effects in the dose range from 0.1 mg to 1 mg tested in the lung implantation model. From the results presented here, it cannot be excluded that tumor development may occur when testing higher doses. BaP, however, must be considered much more potent since it revealed, by far, higher tumor incidences and diminished life times.
以蜂蜡/三辛酸甘油酯混合物为载体,将吖啶、苯并[a]吖啶(BaAC)、苯并[c]吖啶(BcAC)、二苯并[a,h]吖啶(DBa,hAC)和二苯并[a,j]吖啶(DBa,jAC)各三种剂量分别注入每组35只雌性奥斯本-孟德尔大鼠的肺部。为比较这些杂环化合物的致癌效力,以苯并[a]芘(BaP)作为参考物质。获得了DBa,hAC以及BaP的剂量-反应关系。在肺植入模型中测试的0.1毫克至1毫克剂量范围内,DBa,jAC和BcAC未表现出致癌作用。根据此处给出的结果,不能排除在测试更高剂量时可能会发生肿瘤发展的情况。然而,BaP必须被认为更具致癌性,因为到目前为止,它显示出更高的肿瘤发生率和更短的寿命。